Insider Trading March 12, 2026

Enovis Chief Administrative Officer Purchases $23,930 of Company Stock

Engert Oliver adds 1,000 shares as Enovis reports mixed Q4 results and issues 2026 guidance

By Derek Hwang ENOV
Enovis Chief Administrative Officer Purchases $23,930 of Company Stock
ENOV

Engert Oliver, chief administrative officer of Enovis CORP, purchased 1,000 shares of the company’s common stock on March 10, 2026, paying a weighted average between $23.75 and $24.10 for a total of $23,930. The transaction increases his direct holdings to 47,640 shares amid mixed fourth-quarter results and guidance that diverges from consensus estimates.

Key Points

  • Engert Oliver purchased 1,000 Enovis shares on March 10, 2026, at a weighted average price of $23.75 to $24.10, totaling $23,930, bringing his direct holdings to 47,640 shares.
  • Enovis beat Q4 2025 EPS expectations with $0.95 versus $0.82 forecast, but revenue of $575.7 million missed the $584.71 million estimate; 2026 guidance showed revenue below consensus, EBITDA in line, and EPS above consensus.
  • Analyst activity includes seven upward earnings revisions and Needham raising its price target to $52 from $49 while maintaining a Buy rating, with confidence tied to 2027 estimates.

Enovis CORP (NYSE:ENOV) reported an insider purchase by Chief Administrative Officer Engert Oliver on March 10, 2026. Oliver acquired 1,000 shares of common stock at a weighted average price between $23.75 and $24.10, for a total consideration of $23,930. Following the trade, Oliver directly holds 47,640 shares of Enovis.

The purchase occurred while the stock was trading near $23.39 and down roughly 12% year-to-date. InvestingPro analysis cited in company commentary indicates that Enovis may be undervalued at current market levels.


Recent company performance and guidance

Enovis reported fourth-quarter 2025 results that included an earnings-per-share outcome of $0.95, exceeding the consensus forecast of $0.82. The company’s revenue for the quarter was $575.7 million, slightly below the expected $584.71 million.

For 2026, Enovis provided guidance that presented a mixed picture: revenue projections were below consensus estimates, EBITDA guidance was in line with expectations, and EPS guidance was above consensus. Those elements contributed to divergent signals for investors weighing near-term growth versus profitability.


Analyst response and market reaction

Following the disclosure of results and guidance, Needham raised its price target on Enovis to $52 from $49 and retained a Buy rating, citing confidence based on estimates for 2027. InvestingPro Tips cited in company commentary show that seven analysts have revised earnings estimates higher for the upcoming period. Investors are also directed to ENOV’s Pro Research Report, available for this company and more than 1,400 US equities, for additional detail.


What the insider purchase represents

The acquisition by a senior executive increases his direct stake in the company and comes amid a mix of operational signals - an EPS beat, a revenue shortfall for the quarter, and guidance that is split across revenue, EBITDA, and EPS. Market participants looking for context can consider both the insider activity and recent analyst adjustments when assessing the company’s near-term outlook.

All figures and statements above reflect company disclosures and analyst notes provided with the results and the March 10, 2026 transaction filing.

Risks

  • Revenue and guidance uncertainty - Q4 revenue missed estimates and 2026 revenue guidance was provided below consensus, creating uncertainty for top-line momentum; this impacts health-care products and medical device market segments.
  • Mixed financial signals - While EPS beat and EPS guidance were positive, revenue misses and below-consensus revenue guidance create ambiguity for investors in terms of growth versus profitability trade-offs.
  • Market valuation and sentiment - The stock trading down about 12% year-to-date despite insider buying and analyst support highlights potential volatility and differing views among market participants.

More from Insider Trading

Baskett Forest Increases Stake in Korro Bio with $2.3 Million Purchase Mar 12, 2026 Antero Midstream Director Disposes 5,000 Shares as Stock Near 52-Week High Mar 12, 2026 Significant Insider Purchase at Korro Bio: 10% Owner Buys $2.3 Million in Stock Ahead of Earnings Mar 12, 2026 Korro Bio Investor Adds $2.3M in Common Stock as Company Secures New Financing and Analyst Upgrades Mar 12, 2026 Sera Prognostics CIO Disposes Small Stake as Company Advances PreTRM Data and Wins Coverage Mar 12, 2026